Abstract 5657: Anti-hypertensive drugs increase TRAIL sensitivity-induced surface DR5 via autophagy inhibition pathway in prostate cancer cells

Abstract

Abstract Angiotensin II type 1 receptor blockers(ARB) are used as antihypertensive agents, The cohort study found that among people with prostate cancer, thus taking Angiotensin II type 1 receptor blockers had reduced risk ratio. This study investigated that can ARB treatment enhance the TRAIL-mediated prostate cancer cell apoptosis, and the detailed molecular mechanisms. The results showed that ARB treatment increased the TRAIL-mediated prostate cancer cell apoptosis. In the mechanism study, ARB treatment increased DR5 protein expression level, surface DR5 protein amount, and DR5 protein stability. Furthermore, the Regulation of DR5 expression was mediated by autophagy flux inhibition followed by ARB treatment. Taken together, the results demonstrated that ARB treatment sensitized prostate cancer cells to TRAIL-induced apoptosis via autophagy inhibition and DR5 protein stabilization, and also suggest that the prostate cancer cells of ARB taken-patient may be sensitized to TRAIL-mediated apoptosis, and may support the mechanism of cohort study which showed reduction of prostate cancer risk ratio in patient taking angiotensin II type 1 receptor blockers. Citation Format: sang-youel park, Jong-Hun Kim, Jeong-Min Hong, Jae-Won Seol. Anti-hypertensive drugs increase TRAIL sensitivity-induced surface DR5 via autophagy inhibition pathway in prostate cancer cells [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 5657.